ClinicalTrials.gg
RecruitingNCT06970639Updated Aug 13, 2026

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

A Phase 3 interventional study of Furmonertinib Mesilate Tablets and Carboplatin Injection in NSCLC Patients With Brain Metastasis, sponsored by Allist Pharmaceuticals, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2024, registered Apr 2025).
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
71st of 401
380 · median 90
Started
2024
with 44 others
Phase 3
75 of 485
21 open now
Primary completion
2029-03
later than 235 of 262 live
Registered
370th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 71st largest by planned enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2024, is one of 75 in phase 3, reaches primary completion later than 235 of the 262 other live ones, and was the 370th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm A) versus osimertinib monotherapy (Arm B) in patients with EGFR sensitizing mutation-positive non-squamous non-small cell lung cancer (NSCLC) and brain metastases. Additionally, a proportion of subjects will receive furmonertinib monotherapy (Arm C) to further explore its efficacy and safety profile.

Stage 1 is the safety run-in phase, planned to enroll approximately 30 subjects who will be randomized at a 1:1 ratio to receive either furmonertinib 80 mg QD plus platinum-based chemotherapy or furmonertinib 160 mg QD plus platinum-based chemotherapy, aiming to evaluate the safety and tolerability of different furmonertinib doses in combination with platinum-based chemotherapy.

Stage 2 is the randomized controlled phase, in which approximately 350 subjects will be randomized in a 3:3:1 ratio (Arm A : Arm B : Arm C) to receive the investigational treatments.

03

Conditions studied

  • NSCLC Patients With Brain Metastasis

Browse trials for

Keywords

  • EGFR
  • firmonertinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the trial and voluntarily sign the form;
  2. Age ≥18 years at the time of signing ICF, regardless of gender;
  3. Histologically/ confirmed non-squamous NSCLC with brain parenchymal assessed by BICR; Subjects with both brain parenchymal and are eligible. Subjects without may be enrolled in the safety run-in phase.
  4. For subjects with brain metastases: clinically stable for ≥4 weeks prior to first dose AND no requirement for /anticonvulsants for ≥14 days prior to first dose; Investigator-confirmed no need for local therapy for brain metastases during screening.
  5. Confirmed EGFR sensitizing mutations (ex19del or L858R) via tumor tissue/cytology/blood testing;
  6. No prior systemic anti-tumor therapy for advanced/metastatic NSCLC; Subjects who received (neo) chemotherapy or definitive chemoradiotherapy must have disease recurrence/progression ≥6 months after completion;
  7. ≥1 measurable intracranial AND extracranial lesion(s) per v1.1 without prior local treatment;
  8. PS 0-1 with no deterioration within 2 weeks prior to first dose, and ≥3 months;
  9. Adequate bone marrow and organ function (no transfusion/G-CSF within 2 weeks prior to first dose);
  10. All prior treatment-related toxicities resolved to ≤Grade 1 (per v5.0) except alopecia (≤Grade 2) or peripheral neuropathy (≤Grade 2);
  11. Women of (WOCBP) must have negative serum pregnancy test within 7 days prior to first dose, be non-lactating, and use effective from ICF signing until 6 months after last dose. Male subjects with fertile partners must use contraception during the same period.

Exclusion criteria

Exclusion Criteria:

  1. The tumor histology or cytology confirmed that the combination of neuroendocrine carcinoma, sarcomatoid carcinoma or squamous cell carcinoma was more than 10%;
  2. Known subjects with ALK positive, ros1 positive, RET fusion positive, ntrk fusion positive, BRAF V600 mutation, met exon 14 skipping variant and other approved drugs for this target;
  3. Subjects with meningeal but no brain parenchymal metastasis confirmed by MRI and / or CSF malignant cell examination;
  4. Subjects who have previously received any of the following treatments:

    1. Have received any systemic anti-tumor therapy targeting EGFR in the past, including those in clinical research stage (including EGFR TKI, monoclonal antibody, bispecific antibody, etc.);
    2. Previously received systemic antitumor therapy (such as chemotherapy, targeted therapy, immunotherapy, etc.) for locally advanced / metastatic non-small cell lung cancer;
    3. Received > 30 Gy of chest radiotherapy within 6 months before the first dose; Received non thoracic radiotherapy of >30 Gy within 4 weeks before the first dose; Received palliative radiotherapy ≤ 30Gy within 2 weeks before the first dose; Previous brain radiotherapy;
  5. Chinese patent medicine that has received non-specific immune modulators (including but not limited to interferon and IL-2) and approved anti-tumor indications within 2 weeks before the first administration;
  6. Have used any strong inhibitor of cytochrome P450 3A4 () within 7 days before the first administration or any strong inducer of CYP3A4 within 21 days before the first administration;
  7. Other malignant tumors in addition to the primary tumor; Skin basal cell or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, breast ductal carcinoma in situ and papillary thyroid cancer that can be treated locally and have been cured can be selected; Subjects with a history of other and who have been cured for ≥ 3 years after radical treatment can be enrolled;
  8. subjects with known brain stem metastasis, spinal cord metastasis and / or compression; Subjects with acute or progressive intracranial hypertension related symptoms during the screening period; Subjects with brain herniation or near brain herniation; Brain imaging revealed significant brain midline deviation and other subjects requiring urgent local treatment;
  9. According to 5.0, there were subjects with grade 2 headache, vomiting, papilledema, etc. caused by increased intracranial pressure during the screening period; Subjects with grade 2 sensory / motor impairment and visual field damage caused by brain metastasis during the screening period; Subjects with mental symptoms (such as dementia, sluggish reaction, etc.) or seizures caused by brain metastasis during the screening period; Subjects who can control relevant central nervous system symptoms ≤ 1 grade by hormones or anticonvulsants can be enrolled;
  10. The tumor invades the surrounding important organs and blood vessels (such as the heart, esophagus, superior vena cava, etc.) or has the risk of esophago tracheal fistula or esophago pleural fistula;
  11. Cardiovascular and cerebrovascular disease or cardiovascular and cerebrovascular risk factors exist.
  12. There are uncontrollable systemic diseases.
  13. There is a history of (non infectious) interstitial lung disease (ILD) or non infectious pneumonia requiring steroid treatment.
  14. Pulmonary complications lead to clinically severe lung damage.
  15. Severe acute or chronic infection
  16. Subjects who are receiving long-term systemic corticosteroid therapy with prednisone > 10 mg/d or equivalent anti-inflammatory active drugs or any form of therapy before the first administration [subjects who need bronchodilators, inhaled or topical steroids or local steroid injection therapy, or as preventive medication for reactions (such as medication before CT examination, etc.), or to control central nervous system symptoms in patients with brain metastasis can be included in the study];
  17. Subjects who had undergone major surgery within 4 weeks before the first dose or were expected to undergo major surgery during the study;
  18. Bleeding symptoms with significant clinical significance or obvious bleeding tendency within 4 weeks before the first administration.
  19. Severe gastrointestinal dysfunction is known.
  20. Known or suspected allergy to the ingredients of the study drug or its analogues;
  21. Pregnant or lactating women or female subjects who plan to become pregnant during the study or within 6 months after the last dose;
  22. In the judgment of the investigator, the subject has other factors that may affect the results of the study or cause the forced termination of the study, such as alcohol abuse, drug abuse, suffering from other serious diseases (including mental diseases) requiring combined treatment, serious abnormal laboratory test values, family or social factors and other conditions that may affect the safety of the subject or the collection of test data.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Furmonertinib combined with chemotherapy

    Furmonertinib Mesilate Tablets+Carboplatin Injection/Cisplatin for injection+Pemetrexed Disodium for Injection

    Drug: Furmonertinib Mesilate Tablets · Drug: Carboplatin Injection · Drug: Cisplatin for injection · Drug: Pemetrexed Disodium for Injection

  • Active comparator
    Osimertinib Mesylate Tablets

    Osimertinib Mesylate Tablets

    Drug: Osimertinib Mesylate Tablets

Interventions

  • Usage and dosage: 80mg, 240mg, or 160mg QD orally Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs

  • Usage and dosage: Administer via IV infusion, with a dosage of AUC5, not exceeding 750 mg. Medication schedule: every 3 weeks as a cycle, D1 administration per cycle, immediate administration of carboplatin upon completion of pemetrexed infusion, intravenous infusion, carboplatin can be used for up to 4 cycles.

  • Usage and dosage: Administer via IV infusion at a dose of 75 mg/m2. Medication schedule: Every 3 weeks as a cycle, with D1 administration per cycle. Cisplatin is administered approximately 30 minutes after the infusion of pemetrexed, via intravenous infusion. Adequate hydration therapy must be received before and after cisplatin treatment. Cisplatin can be used for up to 4 cycles.

  • Usage and dosage: Intravenous (IV) infusion administration, dosage of 500 mg/m2 Medication schedule: Administer on the first day of each cycle (21 days per cycle, i.e. every 3 weeks) until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs.

  • Usage and dosage: 80mg, QD administration Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    Safe import period

    Time frame: Up to 4 years

  2. Serious Adverse Event (SAE)

    Safe import period

    Time frame: Up to 4 years

  3. Progression-free survival (PFS)

    Randomized Controlled Phase:PFS assessed by BICR based on recist1.1; PFS was defined as the time from the date of randomization to the date of first documented disease progression (assessed according to RECIST v1.1 criteria) or death from any cause, whichever occurred first.

    Time frame: Up to 4 years

Secondary outcomes

  1. Progression free survival (PFS) evaluated by researchers based on RECIST 1.1

    Both the safe introduction period and randomized controlled trials require evaluation of progression free survival (PFS)

    Time frame: Up to 4 years

  2. Objective response rate (ORR)

    Both the safe introduction period and randomized controlled trials require evaluation of objective response rate (ORR)

    Time frame: Up to 4 years

  3. Disease control rate (DCR)

    Both the safe introduction period and randomized controlled trials require evaluation of disease control rate (DCR)

    Time frame: Up to 4 years

  4. Duration of Relief (DOR)

    Both the safe introduction period and randomized controlled trials require evaluation of Duration of Relief (DOR)

    Time frame: Up to 4 years

  5. Overall survival (OS)

    safe introduction period

    Time frame: Up to 4 years

  6. InterPlanetary File System(iPFS) by researchers and BICR based on RECIST 1.1 evaluation

    Randomized Controlled Phase

    Time frame: Up to 4 years

  7. Depth of Response(DepOR) by researchers and BICR based on RECIST 1.1 evaluation

    Randomized Controlled Phase

    Time frame: Up to 4 years

  8. adverse events (AE)

    Randomized Controlled Phase

    Time frame: Up to 4 years

  9. serious adverse events (SAE)

    Randomized Controlled Phase

    Time frame: Up to 4 years

  10. Patient Reported Outcomes by EORTC QLQ LC13 questionnaire

    Randomized Controlled Phase:To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL).

    Time frame: Up to 4 years

  11. Patient Reported Outcomes by EORTCQLQ-C30 questionnaire

    Randomized Controlled Phase:To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL).

    Time frame: Up to 4 years

  12. Peak Plasma Concentration (Cmax)

    Randomized Controlled Phase

    Time frame: Up to 4 years

  13. Steady-state oral clearance(CLss/F)

    Randomized Controlled Phase

    Time frame: Up to 4 years

  14. Steady-state minimal concentration(Cmin,ss)

    Randomized Controlled Phase

    Time frame: Up to 4 years

  15. Steady-state area under the curve(AUCss)

    Randomized Controlled Phase

    Time frame: Up to 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2029, 54 months after the start.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's planned 54 months is above that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
May 14, 2025
StartActual
Sep 26, 2024
Primary completionEst.
Mar 2029
CompletionEst.
Sep 2029
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06970639
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Sep 26, 2024
Primary completion
Mar 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 13, 2026

Study contacts

Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
Contact
zhenhua.gong@allist.com.cn
021-80423288

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion